Lenalidomide is efficient in reducing red blood cell transfusion dependency and markedly lowering platelet counts in MDS/MPN-RS-T in the context of major platelet counts.
Keywords: lenalidomide; myelodysplastic syndrome; myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombosis; myeloproliferative syndrome; thrombocytosis.
© 2020 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.